Search

Displaying results 2171 - 2180 of 10000 in total
  1. Drug

    Fospropofol

    go.drugbank.com/drugs/DB06716
    ApprovedIllicitInvestigationalWithdrawn

    Unlike propofol, does not cause injection-site pain as it is unable to activate TRPA1. FDA approved in December 2008.

  2. Drug

    Zanthoxylum clava-herculis whole

    go.drugbank.com/drugs/DB14353
    Approved

    Zanthoxylum clava-herculis whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  3. Drug

    Ifosfamide

    go.drugbank.com/drugs/DB01181
    ApprovedInvestigational

    Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

    Products: IFO-CELL N 1000, IFO-cell N 1000; Solution for Infusion (1000mg per vial)
  4. Drug

    Thiocolchicoside

    go.drugbank.com/drugs/DB11582
    Investigational

    It has potent convulsant activity and should not be administered to individuals prone to seizures.[L1663]

    Mixtures: TIYOKAS 25MG/4MG SAŞE, 20 SAŞE, TIYOKAS 25MG/8MG SAŞE, 14 SAŞE
  5. Drug

    Clodronic acid

    go.drugbank.com/drugs/DB00720
    ApprovedInvestigationalVet approved

    [A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910]

  6. Drug

    Ferric sulfate

    go.drugbank.com/drugs/DB11171
    Approved

    [A32355, A32356] By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).[L2003] … It is produced by the reaction of sulfuric acid and an oxidizing agent.

  7. Drug

    Sulbactam

    go.drugbank.com/drugs/DB09324
    ApprovedInvestigational

    [L50131] When given in combination with β-lactam antibiotics, sulbactam produces a synergistic effect as it blocks the enzyme responsible for drug resistance by hydrolyzing β-lactams.[A263296]

  8. Drug

    CTx-PDE6b

    go.drugbank.com/drugs/DB17858
    Investigational

    CTx-PDE6b is an adeno-associated virus (AAV) based gene therapy designed to deliver a full-length non-mutated copy of the functional human _PDE6b_ gene. … Being commercialied by Coave Therapeutics, it is being investigated for the treatment of retinitis pigmentosa due to _PDE6b_ gene mutations.[L46757]

  9. Drug

    Pancrelipase amylase

    go.drugbank.com/drugs/DB11065
    ApprovedInvestigational

    [L2509] The amylases are enzymes that help in the chemical process of digestion by hydrolizing starch into more available saccharide forms. … [L2512] The pancrelipase mixture, including pancrelipase amylase, was developed by Ortho-McNeil-Janssen Pharmaceuticals, Inc and FDA approved on April 12, 2010.[L2510]

  10. Drug

    RPI-78M

    go.drugbank.com/drugs/DB05740
    Experimental

    Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), muscular dystrophy (MD) and amyotrophic lateral sclerosis (ALS).